Cannara Biotech Inc.
LOVE.VTSXVHealthcare
$1.89
+$0.11(+6.18%)
Market Cap$181028256
P/E Ratio—
52W High$2.07
52W Low$1.06
Cannara Biotech Inc. (LOVE.V) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LOVE.V · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-08 | 2024-08 | 2023-08 | 2022-08 | 2021-08 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.08B | $0.06B | $0.04B | $0.02B |
| Cost of Revenue | $0.06B | $0.05B | $0.03B | $0.02B | $0.01B |
| Gross Profit | $0.05B | $0.03B | $0.03B | $0.02B | $0.01B |
| Gross Margin %(computed) | 44.00% | 36.44% | 47.56% | 48.36% | 60.50% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.03B | $0.02B | $0.02B | $0.01B | $0.01B |
| Operating Income | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Operating Margin %(computed) | 20.68% | 12.33% | 20.76% | 10.25% | 1.13% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | $0.02B | $0.00B | $0.01B | $0.00B | ($0.00B) |
| Income Tax Expense | $0.01B | ($0.00B) | $0.00B | ($0.00B) | $0.00B |
| Net Income | $0.01B | $0.01B | $0.01B | $0.00B | ($0.00B) |
| Net Margin %(computed) | 12.18% | 7.88% | 12.13% | 6.43% | -18.18% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.14 | $0.07 | $0.08 | $0.03 | $-0.04 |
| Wtd Avg Shares | 0.09B | 0.09B | 0.09B | 0.09B | 0.08B |
| EBITDA | $0.03B | $0.02B | $0.02B | $0.01B | $0.00B |
| EBITDA Margin %(computed) | 26.26% | 18.55% | 27.54% | 26.62% | 18.94% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · B
Explore more Cannara Biotech Inc. data
About Cannara Biotech Inc. (LOVE.V) Income Statement
Cannara Biotech Inc. (LOVE.V) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LOVE.V reported revenue of $0.11B, gross profit of $0.05B (gross margin 44.00%), and net income of $0.01B — a net profit margin of 12.18%.
Frequently asked questions
LOVE.V · 4 questionsCannara Biotech Inc. (LOVE.V) reported revenue of $0.11B for 2025, up 31.3% year-over-year.
LOVE.V revenueLOVE.V salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08